Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

with our plan to bring picoplatin to the market in 2010.

Third Quarter 2008 Unaudited Financial Results

Cash and investment securities as of September 30, 2008, were $84.0 million, compared with $92.6 million at December 31, 2007. Management believes that the existing cash and investment securities will be adequate to fund the Company's operations at least through the first quarter of 2010.

The Company reported a net loss of $12.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $12.4 million) for the third quarter of 2008 compared with a net loss of $7.0 million ($0.20 diluted loss per share on a loss applicable to common shares of $7.1 million) for the third quarter of 2007. The Company reported a net loss of $34.6 million ($1.01 diluted loss per share on a loss applicable to common shares of $35.0 million) for the nine months ended September 30, 2008, compared with a net loss of $23.2 million ($0.80 diluted loss per share on a loss applicable to common shares of $23.6 million) for the same period in 2007.

There was no revenue for the three and nine months ended September 30, 2008 and 2007.

Total operating expenses for the third quarter of 2008 increased 58 percent to $12.4 million, from $7.9 million for the third quarter of 2007, and increased 44 percent to $35.8 million for the nine months ended September 30, 2008, from $24.9 million for the same period in 2007.

Research and development (R&D) expenses increased 79 percent to $9.0 million for the third quarter of 2008, from $5.1 million for the third quarter of 2007 and increased 50 percent to $24.5 million for the nine months ended September 30, 2008, from $16.4 million for the same period in 2007. The increase in R&D expenses for both the quarter and nine months ended September 30, 2008, resulted primarily from increased costs associated with our picoplatin clinical trials and pre-clinical programs.

General and administrative (G&A)
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... York and London. (PRWEB) September 18, 2014 ... of Computer Aided Engineering software, today announced its new ... will be utilizing the CD-adapco simulation tool, STAR-CCM+® in ... team just announced its participation in the 35th America’s ... the 35th edition of the America’s Cup is sustainability, ...
(Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
(Date:9/18/2014)... in German . ... have won the ,International Space Station Research Competition, with ... prize, the scientists will see the International Space Station ... involves crystallizing two proteins of the hepatitis C virus ... the International Space Station is scheduled to lift off ...
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... According to a new market report published by ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - ... at USD 77607.7 million in 2013 and is expected to ... to reach an estimated value of USD 115474.9 million in ... growing at a rapid pace due to increasing prevalence of ...
Breaking Medicine News(10 mins):Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2Health News:Hepatitis C virus proteins in space 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4
... preventing medical support staff from completing orders for outpatient ... in a marked decrease in low-yield exams for patients, ... of Radiology . Many medical institutions request ... web-based radiology order entry systems. Some systems offer real-time ...
... and acceptance Three new reports describe biomarkers ... excellent and stable allograft function in the absence of ... transplants. Peter Heeger and Bernd Schrppel, at Mount Sinai ... commentary, the importance of these studies and how they ...
... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ...
... predisposition to delivering early, , MONDAY, May 24 (HealthDay News) ... to give birth to a baby who isn,t full-term, a ... who weren,t born early but had one or more siblings ... researchers. , "There was a suspicion that preterm birth might ...
... To prevent rejection of their new kidneys, kidney transplant recipients ... lives. A handful of people, out of the thousands who ... drugs without losing their kidneys. Researchers studying these rare ... their white blood cells, which may one day be used ...
... kids with blood sugar disease , MONDAY, May 24 (HealthDay ... enteroviruses -- which can cause viral meningitis -- and diagnoses ... how the two might be linked, but the findings suggest ... for diabetes in its early stages, lead researcher Antonio Toniolo, ...
Cached Medicine News:Health News:Simple change results in fewer unnecessary imaging exams for patients 2Health News:JCI table of contents: May 24, 2010 2Health News:JCI table of contents: May 24, 2010 3Health News:JCI table of contents: May 24, 2010 4Health News:JCI table of contents: May 24, 2010 5Health News:JCI table of contents: May 24, 2010 6Health News:JCI table of contents: May 24, 2010 7Health News:JCI table of contents: May 24, 2010 8Health News:JCI table of contents: May 24, 2010 9Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 2Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 3Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 4Health News:Women Born Early More Apt to Have Preterm Baby 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Viral Infection Could Be Marker for Type 1 Diabetes 2
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
(Date:9/18/2014)... , Sept. 18, 2014 Just days before ... a three-day quarantine to contain the spread of Ebola, World ... medical relief supplies – thanks to private donations. ... United States , through its affiliate McKesson Medical-Surgical donated ... the entire country of Sierra Leone,s ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3
... Bias, DURHAM, N.C., Sept. 15 Less ... treatment are eventually published in,medical journals, according to ... Oncologist.", (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), ... of Washington and,Fred Hutchinson Cancer Research Center, Seattle, ...
... a novel ... macrolide-related drug class, WATERTOWN, Mass., Sept. ... molecule anti-infective drugs, announced,today the initiation of a Phase 1 ... novel,macrolide-related drug class with a distinct resistance profile. The,clinical development ...
Cached Medicine Technology:Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 2Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 3
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: